• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

较短的抗生素疗程会影响台湾结核病负担高地区的控制工作。

Shorter antibiotic regimens impact the control efforts in high tuberculosis burden regions of Taiwan.

机构信息

Institute of Food Safety and Health Risk Assessment, National Yang-Ming University, Taipei, Taiwan.

Department of Bioenvironmental Systems Engineering, National Taiwan University, Taipei, Taiwan.

出版信息

Int J Infect Dis. 2020 Aug;97:135-142. doi: 10.1016/j.ijid.2020.05.082. Epub 2020 May 29.

DOI:10.1016/j.ijid.2020.05.082
PMID:32474203
Abstract

OBJECTIVES

To assess the potential epidemiological impact and cost-effectiveness of shorter antibiotic regimens in high tuberculosis (TB) burden regions of Taiwan.

METHODS

This study combined the TB population dynamic model and cost-effectiveness analysis with local data to simulate the disease burdens, effectiveness and costs of hypothetical 4-month, 2-month and 7-day regimens compared with the standard regimen.

RESULTS

The main outcomes were the potential of shorter regimens for averted incidence, mortality and disability-adjusted life years, incremental cost-effectiveness ratio and net monetary benefit. Shorter regimens would lower incidence rates and mortality cases in a high TB burden region by an average of 19-33% and 27-41%, respectively, with the potential for cost-effectiveness or cost-saving. The 2-month and 7-day regimens would be more cost-effective than the 4-month regimen. The threshold daily drug prices for achieving cost-effectiveness and cost-saving for 4-month, 2-month and 7-day regimens were $US1, $US2 and $US70, respectively. Such cost-effectiveness would remain, even if the willingness-to-pay threshold was less than one gross domestic product per capita.

CONCLUSIONS

The findings support the inclusion of shorter regimens in global guidelines and regional-scale TB control strategies, which would improve disease control, particularly in settings with high rates of incidence and poor treatment outcomes.

摘要

目的

评估在台湾结核病负担较高地区采用较短抗生素疗程方案的潜在流行病学影响和成本效益。

方法

本研究结合结核病人群动力学模型和成本效益分析,利用当地数据,模拟假设的 4 个月、2 个月和 7 天疗程方案与标准疗程方案相比,在疾病负担、效果和成本方面的情况。

结果

主要结局是较短疗程方案在避免发病、死亡和残疾调整生命年方面的潜力、增量成本效益比和净货币收益。在结核病负担较高的地区,较短的疗程方案平均可降低 19-33%的发病率和 27-41%的死亡率,具有成本效益或成本节约的潜力。2 个月和 7 天疗程方案比 4 个月疗程方案更具成本效益。要实现 4 个月、2 个月和 7 天疗程方案的成本效益和成本节约,每日药物价格的阈值分别为 1 美元、2 美元和 70 美元。即使支付意愿阈值低于人均国内生产总值,这种成本效益仍将存在。

结论

研究结果支持将较短的疗程方案纳入全球指南和区域规模的结核病控制策略中,这将改善疾病控制,特别是在发病率高和治疗效果差的环境中。

相似文献

1
Shorter antibiotic regimens impact the control efforts in high tuberculosis burden regions of Taiwan.较短的抗生素疗程会影响台湾结核病负担高地区的控制工作。
Int J Infect Dis. 2020 Aug;97:135-142. doi: 10.1016/j.ijid.2020.05.082. Epub 2020 May 29.
2
Cost-effectiveness of novel first-line treatment regimens for tuberculosis.新型一线结核病治疗方案的成本效益。
Int J Tuberc Lung Dis. 2013 May;17(5):590-6. doi: 10.5588/ijtld.12.0776.
3
The Impact and Cost-Effectiveness of a Four-Month Regimen for First-Line Treatment of Active Tuberculosis in South Africa.南非用于初治活动性结核病一线治疗的四个月疗程的影响及成本效益
PLoS One. 2015 Dec 30;10(12):e0145796. doi: 10.1371/journal.pone.0145796. eCollection 2015.
4
Cost-effectiveness of treating multidrug-resistant tuberculosis.治疗耐多药结核病的成本效益
PLoS Med. 2006 Jul;3(7):e241. doi: 10.1371/journal.pmed.0030241.
5
Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.贝达喹啉治疗南非利福平耐药结核病的增量成本效果:基于模型的分析。
Appl Health Econ Health Policy. 2018 Feb;16(1):43-54. doi: 10.1007/s40258-017-0352-8.
6
Cost and cost-effectiveness of tuberculosis treatment shortening: a model-based analysis.结核病治疗疗程缩短的成本及成本效益:基于模型的分析
BMC Infect Dis. 2016 Dec 1;16(1):726. doi: 10.1186/s12879-016-2064-3.
7
Cost effectiveness of treating multi-drug resistant tuberculosis by adding Deltyba™ to background regimens in Germany.在德国,在背景治疗方案中添加Deltyba™治疗耐多药结核病的成本效益
Respir Med. 2015 May;109(5):632-41. doi: 10.1016/j.rmed.2015.01.017. Epub 2015 Feb 4.
8
Shortened Tuberculosis Treatment for People with HIV in South Africa. A Model-based Evaluation and Cost-effectiveness Analysis.南非针对 HIV 感染者的结核病治疗疗程缩短。基于模型的评估和成本效益分析。
Ann Am Thorac Soc. 2020 Feb;17(2):202-211. doi: 10.1513/AnnalsATS.201905-418OC.
9
Economic implications of novel regimens for tuberculosis treatment in three high-burden countries: a modelling analysis.三种高负担国家新型结核病治疗方案的经济学影响:建模分析。
Lancet Glob Health. 2024 Jun;12(6):e995-e1004. doi: 10.1016/S2214-109X(24)00088-3.
10
Prospects for advancing tuberculosis control efforts through novel therapies.通过新型疗法推进结核病防治工作的前景。
PLoS Med. 2006 Aug;3(8):e273. doi: 10.1371/journal.pmed.0030273.

引用本文的文献

1
Rethinking Tuberculosis Morbidity Quantification: A Systematic Review and Critical Appraisal of TB Disability Weights in Cost-Effectiveness Analyses.重新思考结核病发病率量化:成本效益分析中结核病残疾权重的系统评价和批判性评估。
Pharmacoeconomics. 2024 Nov;42(11):1209-1236. doi: 10.1007/s40273-024-01410-x. Epub 2024 Aug 7.